Show simple item record

dc.contributor.authorPatel, Jeetesh V.en_US
dc.contributor.authorCummings, David E.en_US
dc.contributor.authorGirod, John P.en_US
dc.contributor.authorMascarenhas, Alwin Y.en_US
dc.contributor.authorHughes, Elizabeth A.en_US
dc.contributor.authorGupta, Manjulaen_US
dc.contributor.authorLip, Gregory Y. H.en_US
dc.contributor.authorReddy, Sethuen_US
dc.contributor.authorBrotman, Daniel J.en_US
dc.date.accessioned2010-04-21T15:50:02Z
dc.date.available2010-04-21T15:50:02Z
dc.date.issued2006en_US
dc.identifier.citationPatel J, Cummings D, Girod J, et al. Role of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatment. Journal of Negative Results in BioMedicine. 2006;5(1):14.en_US
dc.identifier.other10.1186/1477-5751-5-14en_US
dc.identifier.urihttp://www.jnrbm.com/content/5/1/14en_US
dc.identifier.urihttp://hdl.handle.net/1773/15728
dc.description.abstractBackground: The mechanisms by which glucocorticoid therapy promotes obesity and insulin resistance are incompletely characterized. Modulations of the metabolically active hormones, tumour necrosis factor alpha (TNF alpha), ghrelin, leptin and adiponectin are all implicated in the development of these cardiovascular risk factors. Little is known about the effects of short-term glucocorticoid treatment on levels of these hormones. Research methods and procedures: Using a blinded, placebo-controlled approach, we randomised 25 healthy men (mean (SD) age: 24.2 (5.4) years) to 5 days of treatment with either placebo or oral dexamethasone 3 mg twice daily. Fasting plasma TNFa, ghrelin, leptin and adiponectin were measured before and after treatment. Results: Mean changes in all hormones were no different between treatment arms, despite dexamethasone-related increases in body weight, blood pressure, HDL cholesterol and insulin. Changes in calculated indices of insulin sensitivity (HOMA-S, insulin sensitivity index) were strongly related to dexamethasone treatment (p less than 0.001). Discussion: Our data do not support a role for TNF alpha, ghrelin, leptin or adiponectin in the insulin resistance associated with short-term glucocorticoid treatment.en_US
dc.description.sponsorshipThis work was supported by the Cleveland Clinic Foundation Research Programs Council and the National Institutes of Health [R01 DK61516].en_US
dc.language.isoen_USen_US
dc.titleRole of metabolically active hormones in the insulin resistance associated with short-term glucocorticoid treatmenten_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record